SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Information Statement Pursuant to Rules 13d‑1 and 13d‑2
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Aquestive Therapeutics, Inc.
(Name of Issuer)
Common Stock, Par Value $0.001 Per Share
(Title of Class of Securities)
03843E104
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
/ / Rule 13d-1(b)
/ / Rule 13d-1(c)
/X/ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
**The total number of shares reported herein is 11,585,054 shares, which constitutes approximately 46.3% of the total number of shares outstanding. All ownership percentages set forth herein assume that there are 25,042,964 shares outstanding.
CUSIP No. 03843E104
1. Name of Reporting Person:
MonoLine RX II, L.P.
2. Check the Appropriate Box if a Member of a Group:
(a) / /
(b) / X /
3. SEC Use Only
4. Citizenship or Place of Organization: Texas
5. Sole Voting Power: 4,032,907
Number of
Shares
Beneficially 6. Shared Voting Power: -0-
Owned By
Each
Reporting 7. Sole Dispositive Power: 4,032,907
Person
With
8. Shared Dispositive Power: -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
4,032,907
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
/ /
11. Percent of Class Represented by Amount in Row (9): 16.1%
12. Type of Reporting Person: PN
--------------
CUSIP No. 03843E104
1. Name of Reporting Person:
MonoLine Rx III, L.P.
2. Check the Appropriate Box if a Member of a Group:
(a) / /
(b) / X /
3. SEC Use Only
4. Citizenship or Place of Organization: Texas
5. Sole Voting Power: 2,755,541
Number of
Shares
Beneficially 6. Shared Voting Power: -0-
Owned By
Each
Reporting 7. Sole Dispositive Power: 2,755,541
Person
With
8. Shared Dispositive Power: -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
2,755,541
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
/ /
11. Percent of Class Represented by Amount in Row (9): 11.0%
12. Type of Reporting Person: PN
--------------
CUSIP No. 03843E104
1. Name of Reporting Person:
MRX Partners, LLC
2. Check the Appropriate Box if a Member of a Group:
(a) / /
(b) / X /
3. SEC Use Only
4. Citizenship or Place of Organization: Texas
5. Sole Voting Power: 2,249,077
Number of
Shares
Beneficially 6. Shared Voting Power: -0-
Owned By
Each
Reporting 7. Sole Dispositive Power: 2,249,077
Person
With
8. Shared Dispositive Power: -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
2,249,077
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
/ /
11. Percent of Class Represented by Amount in Row (9): 9.0%
12. Type of Reporting Person: OO
--------------
CUSIP No. 03843E104
1. Name of Reporting Person:
MonoLine Rx, L.P.
2. Check the Appropriate Box if a Member of a Group:
(a) / /
(b) / X /
3. SEC Use Only
4. Citizenship or Place of Organization: Texas
5. Sole Voting Power: 2,213,314
Number of
Shares
Beneficially 6. Shared Voting Power: -0-
Owned By
Each
Reporting 7. Sole Dispositive Power: 2,213,314
Person
With
8. Shared Dispositive Power: -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
2,213,314
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
/ /
11. Percent of Class Represented by Amount in Row (9): 8.8%
12. Type of Reporting Person: PN
--------------
CUSIP No. 03843E104
1. Name of Reporting Person:
MonoLine Partners, L.P.
2. Check the Appropriate Box if a Member of a Group:
(a) / /
(b) / X /
3. SEC Use Only
4. Citizenship or Place of Organization: Texas
5. Sole Voting Power: 165,000
Number of
Shares
Beneficially 6. Shared Voting Power: -0-
Owned By
Each
Reporting 7. Sole Dispositive Power: 165,000
Person
With
8. Shared Dispositive Power: -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
165,000
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
/ /
11. Percent of Class Represented by Amount in Row (9): 0.7%
12. Type of Reporting Person: PN
--------------
CUSIP No. 03843E104
1. Name of Reporting Person:
MonoSol Rx Genpar, L.P.
2. Check the Appropriate Box if a Member of a Group:
(a) / /
(b) / X /
3. SEC Use Only
4. Citizenship or Place of Organization: Texas
5. Sole Voting Power: 87,455
Number of
Shares
Beneficially 6. Shared Voting Power: -0-
Owned By
Each
Reporting 7. Sole Dispositive Power: 87,455
Person
With
8. Shared Dispositive Power: -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
87,455
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
/ /
11. Percent of Class Represented by Amount in Row (9): 0.3%
12. Type of Reporting Person: PN
--------------
CUSIP No. 03843E104
1. Name of Reporting Person:
Douglas K. Bratton
2. Check the Appropriate Box if a Member of a Group:
(a) / /
(b) / X /
3. SEC Use Only
4. Citizenship or Place of Organization: United States
5. Sole Voting Power: 11,578,379(1)(2)
Number of
Shares
Beneficially 6. Shared Voting Power: -0-
Owned By
Each
Reporting 7. Sole Dispositive Power: 11,578,379(1)(2)
Person
With
8. Shared Dispositive Power: -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
11,585,054
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
/ /
11. Percent of Class Represented by Amount in Row (9): 46.3%
12. Type of Reporting Person: IN
--------------
(1) 81,760 of such shares are owned directly by Douglas K. Bratton, 6,675 of which are shares that Mr. Bratton currently has the right to acquire under vested director stock options.
| (2) | Bratton Capital Management L.P. is the general partner of each of the Reporting Persons except for MonoSol Rx Genpar, L.P., the general partner of which is Bratton Capital Inc., which, in turn, is the general partner of Bratton Capital Management L.P. Douglas K. Bratton (“DKB”) is the sole director and President of Bratton Capital Inc. and exercises voting and dispositive power over all shares reported herein. |
Pursuant to Rule 13d‑2(b) of Regulation 13D‑G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the "Act"), the undersigned hereby amend their Schedule 13G Statement dated February 13, 2019 (the "Schedule 13G"), relating to the Common Stock, par value $0.001 per share (the "Stock"), of Aquestive Therapeutics, Inc. (the "Issuer"). Unless otherwise indicated, all defined terms used herein shall have the same meanings as those set forth in the Schedule 13G.
Item 4 is hereby amended and restated in its entirety as follows:
Item 4. Ownership.
(a) - (b)
Reporting Persons
MonoLine II
The aggregate number of shares of the Stock that MonoLine II owns beneficially, pursuant to Rule 13d‑3 of the Act, is 4,032,907, which constitutes approximately 16.1% of the outstanding shares of the Stock.
MonoLine III
The aggregate number of shares of the Stock that MonoLine III owns beneficially, pursuant to Rule 13d‑3 of the Act, is 2,755,541, which constitutes approximately 11.0% of the outstanding shares of the Stock.
MRX Partners
The aggregate number of shares of the Stock that MRX Partners owns beneficially, pursuant to Rule 13d‑3 of the Act, is 2,249,077, which constitutes approximately 9.0% of the outstanding shares of the Stock.
MonoLine Rx
The aggregate number of shares of the Stock that MonoLine Rx owns beneficially, pursuant to Rule 13d‑3 of the Act, is 2,213,314, which constitutes approximately 8.8% of the outstanding shares of the Stock.
MonoLine
The aggregate number of shares of the Stock that MonoLine owns beneficially, pursuant to Rule 13d‑3 of the Act, is 165,000, which constitutes approximately 0.7% of the outstanding shares of the Stock.
Genpar
The aggregate number of shares of the Stock that Genpar owns beneficially, pursuant to Rule 13d‑3 of the Act, is 87,455, which constitutes approximately 0.3% of the outstanding shares of the Stock.
DKB
Because of his individual ownership of 81,760 shares of the Stock, which includes shares that may be acquired currently under 6,675 vested director stock options, and his position as sole director and President of Bratton Inc., which is the general partner of both Genpar and Bratton Capital, which, in turn, is the general partner or manager of each of the other Reporting Persons, DKB may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of an aggregate of 11,585,054 shares of the Stock, which constitutes approximately 46.3% of the outstanding shares of the Stock.
Controlling Persons
Bratton Capital
Because of its position as (i) the general partner of each of MonoLine II, MonoLine III, MonoLine Rx, and MonoLine and (ii) the manager of MRX Partners, Bratton Capital may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of 11,415,839 shares of the Stock, which constitutes approximately 45.6% of the outstanding shares of the Stock.
Bratton Inc.
Because of its position as the general partner of both Genpar and Bratton Capital, Bratton Inc. may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of 11,503,294 shares of the Stock, which constitutes approximately 46.0% of the outstanding shares of the Stock.
To the best of the knowledge of the Reporting Persons, other than as set forth above, none of the persons named in Item 2 herein is the beneficial owner of any shares of the Stock.
(c)
Reporting Persons
MonoLine II
Acting through its general partner, MonoLine II has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 4,032,907 shares of the Stock.
MonoLine III
Acting through its general partner, MonoLine III has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 2,755,541 shares of the Stock.
MRX Partners
Acting through its manager, MRX Partners has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 2,249,077 shares of the Stock.
MonoLine Rx
Acting through its general partner, MonoLine Rx has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 2,213,314 shares of the Stock.
MonoLine
Acting through its general partner, MonoLine has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 165,000 shares of the Stock.
Genpar
Acting through its general partner, Genpar has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 87,455 shares of the Stock.
DKB
In his individual capacity, DKB has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 75,085 shares of the Stock. In addition, in his capacity as the sole director and President of Bratton Inc., which is the general partner of both Genpar and Bratton Capital, DKB has the sole power to vote or to direct the vote and to dispose or to direct the disposition of 11,503,294 shares of the Stock.
Controlling Persons
Bratton Capital
In its capacity as (i) the general partner of each of MonoLine II, MonoLine III, MonoLine Rx, and MonoLine, and (ii) the manager of MRX Partners, Bratton Capital has the sole power to vote or to direct the vote and to dispose or to direct the disposition of an aggregate of 11,415,839 shares of the Stock.
Bratton Inc.
In its capacity as (i) the general partner of Genpar, and (ii) the general partner of Bratton Capital, Bratton Inc. has the sole power to vote or to direct the vote and to dispose or to direct the disposition of an aggregate of 11,503,294 shares of the Stock.
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
DATED: February 12, 2020
MONOLINE RX II, L.P.
By: Bratton Capital Management, L.P., general partner
By: Bratton Capital, Inc., general partner
By: /s/ John Cochran
John Cochran, Vice President
MONOLINE RX III, L.P.
By: Bratton Capital Management, L.P., general partner
By: Bratton Capital, Inc., general partner
By: /s/ John Cochran
John Cochran, Vice President
MRX PARTNERS, LLC
By: Bratton Capital Management, L.P., manager
By: Bratton Capital, Inc., general partner
By: /s/ John Cochran
John Cochran, Vice President
MONOLINE RX, L.P.
By: Bratton Capital Management, L.P., general partner
By: Bratton Capital, Inc., general partner
By: /s/ John Cochran
John Cochran, Vice President
MONOLINE PARTNERS, L.P.
By: Bratton Capital Management, L.P., general partner
By: Bratton Capital, Inc., general partner
By: /s/ John Cochran
John Cochran, Vice President
MONOSOL RX GENPAR, L.P.
By: Bratton Capital, Inc., general partner
By: /s/ John Cochran
John Cochran, Vice President
/s/ DOUGLAS K. BRATTON
DOUGLAS K. BRATTON
